Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

Phase 1

Recruiting

Conditions: Lupus Nephritis - WHO Class III
Refractory Systemic Lupus Erythematosus
Lupus Nephritis - WHO Class IV

Interventions: Drug: AB-101
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Rituximab
Drug: Obinutuzumab

First Posted Date: 2024-02-20

Last Posted Date: 2024-07-12

Lead Sponsor: Artiva Biotherapeutics, Inc.

Target Recruit Count: 51

Registration Number: NCT06265220

Locations: 🇺🇸
University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States
🇺🇸
University of California, San Diego, San Diego, California, United States

CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia in Children

Interventions: Drug: Quizartinib
Drug: Etoposide
Drug: Dexrazoxane
Drug: Mitoxantrone
Drug: Cytarabine
Drug: Methotrexate
Drug: Daunorubicin
Drug: Fludarabine
Other: allo-SCT

First Posted Date: 2024-02-16

Last Posted Date: 2024-02-16

Lead Sponsor: Princess Maxima Center for Pediatric Oncology

Target Recruit Count: 60

Registration Number: NCT06262438

Locations: 🇳🇱
Princess Máxima Center for pediatric oncology, Utrecht, Netherlands

Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Phase 2

Recruiting

Conditions: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Relapsed/Refractory Mantle Cell Lymphoma

Interventions: Drug: KTE-X19
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2024-02-12

Last Posted Date: 2024-12-03

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 21

Registration Number: NCT06253663

Locations: 🇯🇵
Kyushu University Hospital, Fukuoka, Japan
🇯🇵
Hokkaido University Hospital, Hokkaido, Japan
🇯🇵
Tohoku University Hospital, Miyagi, Japan

and more 5 locations

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation

Phase 2

Recruiting

Conditions: Hematologic Malignancy
Graft Versus Host Disease

Interventions: Drug: Methotrexate
Drug: Post-Transplant Cyclophosphamide
Drug: Fludarabine
Drug: Cycophosphamide
Drug: Anti-Thymoglobulin
Other: Donor Lymphocytes Injection
Radiation: total body irradiation
Other: hematopoietic stem cells
Drug: Thiotepa
Other: Graft nuclear cells
Drug: Busulfan
Drug: Clofarabine

First Posted Date: 2024-02-12

Last Posted Date: 2024-10-28

Lead Sponsor: Nantes University Hospital

Target Recruit Count: 82

Registration Number: NCT06252870

Locations: 🇫🇷
CHU Angers, Angers, France
🇫🇷
CHU Brest, Brest, France
🇫🇷
CHU Nantes, Nantes, France

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Phase 1

Recruiting

Conditions: Non-Small Cell Lung Cancer
Gastrointestinal Cancer
Ovarian Cancer
Metastatic Solid Cancers
Colorectal Cancer
Breast Cancer
Genitourinary Cancer

Interventions: Drug: Aldesleukin
Drug: Fludarabine
Drug: Cyclophosphamide
Biological: KRAS TCR-Transduced PBL
Biological: GRT-C903/GRT-R904

First Posted Date: 2024-02-12

Last Posted Date: 2025-01-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 210

Registration Number: NCT06253520

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Phase 1

Recruiting

Conditions: Recurrent Childhood Acute Myeloid Leukemia
Recurrent Childhood Myelodysplastic Syndrome
Recurrent Juvenile Myelomonocytic Leukemia
Refractory Childhood Acute Myeloid Leukemia
Refractory Childhood Myelodysplastic Syndrome
Refractory Juvenile Myelomonocytic Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Cytarabine
Procedure: Echocardiography
Drug: Fludarabine
Drug: Hydrocortisone Sodium Succinate
Biological: Imetelstat
Drug: Leucovorin Calcium
Procedure: Lumbar Puncture
Drug: Methotrexate

First Posted Date: 2024-02-08

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 36

Registration Number: NCT06247787

Locations: 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
C S Mott Children's Hospital, Ann Arbor, Michigan, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

and more 10 locations

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: FT825
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Bendamustine
Drug: Docetaxel
Drug: Cisplatin
Drug: Cetuximab

First Posted Date: 2024-02-05

Last Posted Date: 2024-12-24

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 351

Registration Number: NCT06241456

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
University of California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
Yale New Haven Hospital - Yale Cancer Center, New Haven, Connecticut, United States

and more 12 locations

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Lung Neoplasms
Advanced Solid Tumor
Melanoma
Head and Neck Neoplasms

Interventions: Drug: KSQ-001EX
Drug: Cyclophosphamide
Drug: Interleukin-2
Drug: Fludarabine

First Posted Date: 2024-02-02

Last Posted Date: 2024-10-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 72

Registration Number: NCT06237881

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1

Recruiting

Conditions: Castration-Resistant Prostate Carcinoma
Metastatic Prostate Adenocarcinoma
Stage IVB Prostate Cancer AJCC v8

Interventions: Biological: Anti-STEAP1 CAR T-cells
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Computed Tomography
Drug: Cyclophosphamide
Procedure: Echocardiography
Drug: Enzalutamide
Drug: Fludarabine
Procedure: Leukapheresis
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan
Procedure: Positron Emission Tomography

First Posted Date: 2024-02-01

Last Posted Date: 2024-12-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 48

Registration Number: NCT06236139

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Phase 1

Recruiting

Conditions: Squamous Cell Carcinoma of Head and Neck
Metastatic Squamous Cell Carcinoma

Interventions: Biological: TBio-4101
Drug: Pembrolizumab
Drug: Platinum based chemotherapy
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Aldesleukin

First Posted Date: 2024-02-01

Last Posted Date: 2024-11-29

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 15

Registration Number: NCT06236425

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy